ATE495246T1 - Neuartiger shuttle-vektor - Google Patents
Neuartiger shuttle-vektorInfo
- Publication number
- ATE495246T1 ATE495246T1 AT09003552T AT09003552T ATE495246T1 AT E495246 T1 ATE495246 T1 AT E495246T1 AT 09003552 T AT09003552 T AT 09003552T AT 09003552 T AT09003552 T AT 09003552T AT E495246 T1 ATE495246 T1 AT E495246T1
- Authority
- AT
- Austria
- Prior art keywords
- escherichia coli
- region
- shuttle vector
- ptb6
- expression vector
- Prior art date
Links
- 239000013605 shuttle vector Substances 0.000 title abstract 4
- 241000186000 Bifidobacterium Species 0.000 abstract 7
- 241000588724 Escherichia coli Species 0.000 abstract 4
- 239000013604 expression vector Substances 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 108020005091 Replication Origin Proteins 0.000 abstract 2
- 108020004414 DNA Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 101150073130 ampR gene Proteins 0.000 abstract 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 abstract 1
- 229960000723 ampicillin Drugs 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 244000005700 microbiome Species 0.000 abstract 1
- 210000004897 n-terminal region Anatomy 0.000 abstract 1
- 239000013612 plasmid Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Structure Of Belt Conveyors (AREA)
- Variable-Direction Aerials And Aerial Arrays (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004339677 | 2004-11-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE495246T1 true ATE495246T1 (de) | 2011-01-15 |
Family
ID=36498025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT09003552T ATE495246T1 (de) | 2004-11-24 | 2005-11-24 | Neuartiger shuttle-vektor |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8021653B2 (de) |
| EP (2) | EP2088193B1 (de) |
| JP (1) | JP4989231B2 (de) |
| KR (1) | KR101243662B1 (de) |
| CN (1) | CN101065482B (de) |
| AT (1) | ATE495246T1 (de) |
| CA (1) | CA2586126C (de) |
| DE (1) | DE602005025946D1 (de) |
| DK (1) | DK2088193T3 (de) |
| ES (1) | ES2357372T3 (de) |
| PT (1) | PT2088193E (de) |
| SG (1) | SG158077A1 (de) |
| WO (1) | WO2006057289A1 (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2468861E (pt) * | 2006-05-24 | 2014-12-05 | Anaeropharma Science Inc | Método de construção de suporte de tranporte de genes |
| ES2595729T3 (es) * | 2007-01-12 | 2017-01-03 | Intrexon Actobiotics Nv | Promotores de Lactococcus y usos de los mismos |
| US9730968B2 (en) | 2008-04-17 | 2017-08-15 | Anaeropharma Science, Inc. | Therapeutic agent for ischemic diseases |
| JP5735804B2 (ja) | 2008-04-17 | 2015-06-17 | 株式会社アネロファーマ・サイエンス | 発現ベクター |
| EP2896695A3 (de) | 2010-01-29 | 2015-09-23 | Anaeropharma Science, Inc. | Transformationsplasmid |
| WO2015120541A1 (en) * | 2014-02-14 | 2015-08-20 | Symvivo Corporation | Nucleic acid vectors and uses thereof |
| CN104388419B (zh) * | 2014-10-13 | 2018-01-16 | 华侨大学 | 一种高效扩增核酸分子的方法 |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| BR112018010639A2 (pt) * | 2015-11-24 | 2019-01-22 | Glaxosmithkline Ip Dev Ltd | método de transfecção transitória para produção retroviral. |
| EP3380604B1 (de) * | 2015-11-24 | 2022-12-28 | GlaxoSmithKline Intellectual Property Development Limited | Stabile zelllinien für die retrovirenproduktion |
| KR20170068304A (ko) | 2015-12-09 | 2017-06-19 | 삼성전자주식회사 | 대장균 및 코마가타에이박터 속 세포에서 복제가능한 벡터, 그를 포함한 세포, 및 그를 이용하는 방법 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63309191A (ja) * | 1987-06-09 | 1988-12-16 | Toagosei Chem Ind Co Ltd | プラスミドベクタ− |
| US6110737A (en) | 1988-02-02 | 2000-08-29 | The Regents Of The University Of California | Human platelet-derived growth factor receptor, type A |
| JPH05130876A (ja) * | 1991-04-10 | 1993-05-28 | Morinaga Milk Ind Co Ltd | プラスミドベクター |
| US6190657B1 (en) | 1995-06-07 | 2001-02-20 | Yale University | Vectors for the diagnosis and treatment of solid tumors including melanoma |
| JP3946300B2 (ja) * | 1997-03-27 | 2007-07-18 | 株式会社ヤクルト本社 | ビフィズス菌用シャトルベクター及びビフィズス菌プラスミドの複製タンパク質遺伝子 |
| WO1999013053A1 (en) | 1997-09-10 | 1999-03-18 | Vion Pharmaceuticals, Inc. | Genetically modified tumor-targeted bacteria with reduced virulence |
| US6080849A (en) | 1997-09-10 | 2000-06-27 | Vion Pharmaceuticals, Inc. | Genetically modified tumor-targeted bacteria with reduced virulence |
| JPH11285387A (ja) * | 1998-04-03 | 1999-10-19 | Tdk Corp | 新規なｄｎａ配列及びそれを含むプラスミドベクター |
| AU7572900A (en) | 1999-08-26 | 2001-03-19 | Vion Pharmaceuticals, Inc. | Compositions and methods for delivery of an agent using attenuated salmonella containing phage |
| US6962696B1 (en) | 1999-10-04 | 2005-11-08 | Vion Pharmaceuticals Inc. | Compositions and methods for tumor-targeted delivery of effector molecules |
| JP3642755B2 (ja) | 2000-09-21 | 2005-04-27 | 純 天野 | 嫌気性菌を用いた遺伝子治療用医薬 |
| CA2342040C (en) | 2000-09-21 | 2012-07-10 | Kyowa Hakko Kogyo Co., Ltd. | Anaerobic bacterium as a drug for cancer gene therapy |
| DE60226856D1 (de) * | 2001-04-20 | 2008-07-10 | Penn State Res Found | Verfahren zur manipulation von nukleinsäuren |
| JP2003235565A (ja) * | 2002-02-20 | 2003-08-26 | Yakult Honsha Co Ltd | 乳酸菌用シャトルベクター |
-
2005
- 2005-11-24 AT AT09003552T patent/ATE495246T1/de not_active IP Right Cessation
- 2005-11-24 EP EP09003552A patent/EP2088193B1/de not_active Expired - Lifetime
- 2005-11-24 JP JP2006547820A patent/JP4989231B2/ja not_active Expired - Fee Related
- 2005-11-24 DK DK09003552.8T patent/DK2088193T3/da active
- 2005-11-24 SG SG200907759-5A patent/SG158077A1/en unknown
- 2005-11-24 EP EP05809419A patent/EP1829963A4/de not_active Withdrawn
- 2005-11-24 ES ES09003552T patent/ES2357372T3/es not_active Expired - Lifetime
- 2005-11-24 CN CN2005800400785A patent/CN101065482B/zh not_active Expired - Fee Related
- 2005-11-24 WO PCT/JP2005/021566 patent/WO2006057289A1/ja not_active Ceased
- 2005-11-24 KR KR1020077014237A patent/KR101243662B1/ko not_active Expired - Fee Related
- 2005-11-24 PT PT09003552T patent/PT2088193E/pt unknown
- 2005-11-24 DE DE602005025946T patent/DE602005025946D1/de not_active Expired - Lifetime
- 2005-11-24 CA CA2586126A patent/CA2586126C/en not_active Expired - Lifetime
- 2005-11-24 US US11/718,680 patent/US8021653B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP1829963A1 (de) | 2007-09-05 |
| DK2088193T3 (da) | 2011-02-28 |
| CN101065482B (zh) | 2011-07-13 |
| ES2357372T3 (es) | 2011-04-25 |
| KR20070107671A (ko) | 2007-11-07 |
| SG158077A1 (en) | 2010-01-29 |
| CN101065482A (zh) | 2007-10-31 |
| JPWO2006057289A1 (ja) | 2008-06-05 |
| DE602005025946D1 (de) | 2011-02-24 |
| CA2586126C (en) | 2016-06-28 |
| PT2088193E (pt) | 2011-02-24 |
| EP2088193A1 (de) | 2009-08-12 |
| EP1829963A4 (de) | 2009-01-28 |
| EP2088193B1 (de) | 2011-01-12 |
| KR101243662B1 (ko) | 2013-03-14 |
| US8021653B2 (en) | 2011-09-20 |
| WO2006057289A1 (ja) | 2006-06-01 |
| JP4989231B2 (ja) | 2012-08-01 |
| CA2586126A1 (en) | 2006-06-01 |
| US20100129323A1 (en) | 2010-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602005025946D1 (de) | Neuartiger Shuttle-Vektor | |
| CA2274982A1 (en) | New escherichia coli host/vector system based on antibiotic-free selection by complementation of an auxotrophy | |
| AP1763A (en) | Pulmonary administration of chemically modified insulin | |
| IL174154A (en) | History of GLP-1 New Pharmaceutical Preparations Containing Them and Using It to Make Medicines | |
| AU2001254624A1 (en) | Human coagulation factor vii variants | |
| DE60113851D1 (de) | Bakteriophage mit breitem wirtspektrum | |
| Low et al. | Protected environments allow parallel evolution of a bacterial pathogen in a patient subjected to long‐term antibiotic therapy | |
| PL1675956T3 (pl) | Minimalna sekwencja DNA działająca jako insulator chromatyny i jej zastosowanie do wyrażania białek | |
| DK1425038T4 (da) | Svækkede bakterier, der er anvendelige i vacciner | |
| Gupta et al. | Involvement of residues 147VYYEIGK153 in binding of lethal factor to protective antigen of Bacillus anthracis | |
| Hsiao et al. | Post‐transcriptional cross‐talk between pro‐and anti‐colonization pili biosynthesis systems in Vibrio cholerae | |
| BRPI0318594B8 (pt) | proteína recombinante que possui um efeito anticâncer, seu gene de codificação, seu uso, medicamento para tratar cânceres, vetor de expressão e microrganismo transgênico | |
| MXPA03004539A (es) | Luciferasas aisladas y uso de las mismas. | |
| Sanders et al. | Membrane-spanning and periplasmic segments of CcmI have distinct functions during cytochrome c biogenesis in Rhodobacter capsulatus | |
| Hosseini et al. | Targeting of cholera toxin A (ctxA) gene by zinc finger nuclease: pitfalls of using gene editing tools in prokaryotes | |
| Komine et al. | Physical map locations of the genes that encode small stable RNAs in Escherichia coli | |
| WO2001034810A3 (en) | Genes essential for microbial proliferation | |
| CO5271686A1 (es) | Nuevo uso de (r)-(-)-2-[5-(4-flurofenil)-3-piridilmetil- aminometil]-cromano y de sus sales aceptables para uso fisiologico | |
| WO2001088137A3 (en) | Human myd88 adapter-like protein and functional fragments thereof | |
| ATE481479T1 (de) | Neue plasmide und deren nutzung | |
| Park et al. | GroEL/ES chaperone and low culture temperature synergistically enhanced the soluble expression of CGTase in E. coli | |
| IL174645A0 (en) | MODIFIED cDNA FOR HIGH EXPRESSION LEVELS OF FACTOR VIII AND ITS DERIVATIVES | |
| WO2001088114A3 (en) | Gene expression system | |
| UY26286A1 (es) | Gen de streptomyces avermitilis que dirige la relación de avermectinas b2:b1 | |
| Roy et al. | Reply to Letter to the Editor concerning the recently published article entitled" First report of OXA-484 carbapenemase harbouring clinical isolate of Escherichia coli ST2099 in India: Genome characterization using whole genome sequencing" |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |